Eurasian Congress on Molecular Biotechnology, Trabzon, Turkey, 19 - 21 September 2019, pp.17
Introduction: Urothelial bladder cancer is the third most common malignancy in male population in Turkey. Urothelial bladder cancer with distant metastasis has a 5-year survival rate of 5 %. Five immune checkpoint inhibitors were approved by the US Food and Drug Administration (FDA) for locally advanced or metastatic urothelial bladder cancer patients who progressed during or after platinum therapy. Results of ongoing and completed clinical trials involving these drugs showed promising outcomes for patients previously treated for advanced urothelial bladder cancer. A meta-analysis was performed to assess the efficacy of anti-PD-1/PD-L1 antibodies for advanced urothelial bladder cancer patients from six clinical trials.
Materials and methods: 876 urothelial bladder cancer patients were included. PD-L1 expression data retrieved from reports of clinical trials was analyzed to evaluate patient response to atezolizumab, nivolumab, durvalumab and pembrolizumab treatments.
Results: High PD-L1 expression in patients with urothelial bladder cancer was found to be significantly related to better objective response rate (ORR) after anti-PD-1/PD-L1 antibody treatment (RR: 2.14, 95% CI: 1.12-4.09, P<0.02).
Conclusion: Expression of PD-L1 was associated with significantly better response to PD-1/PD-L1 blockade therapy and can be used as a biomarker to predict ORR.
References: National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: bladder cancer. https://seer.cancer.gov/statfacts/html/urinb.html. Accessed June 14th, 2019.